Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pregnancy loss in individuals with von Willebrand disease and unspecified mucocutaneous bleeding disorders: a multicenter cohort study.
Skeith L, James P, Kouides P, Uminski K, Duffett L, Jackson S, Sholzberg M, Ragni MV, Cuker A, O'Beirne M, Hews-Girard J, Rydz N, Goodyear DM, Baxter J, James A, Garcia D, Vesely SK, Poon MC; VWD Pregnancy Loss Study Group. Skeith L, et al. Among authors: ragni mv. J Thromb Haemost. 2024 Oct 23:S1538-7836(24)00627-5. doi: 10.1016/j.jtha.2024.09.037. Online ahead of print. J Thromb Haemost. 2024. PMID: 39454883 Free article.
Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand.
Álvarez-Román MT, Shapiro AD, Ragni MV, Palmborg H, Bystrická L, Szamosi J, Casiano S, Chambost H. Álvarez-Román MT, et al. Among authors: ragni mv. Res Pract Thromb Haemost. 2023 Aug 9;7(6):102163. doi: 10.1016/j.rpth.2023.102163. eCollection 2023 Aug. Res Pract Thromb Haemost. 2023. PMID: 37720484 Free PMC article.
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.
Ragni MV, Rothenberger SD, Feldman R, Nance D, Leavitt AD, Malec L, Kulkarni R, Sidonio R Jr, Kraut E, Lasky J, Pruthi R, Angelini D, Philipp C, Hwang N, Wheeler AP, Seaman C, Machin N, Xavier F, Meyer M, Bellissimo D, Humphreys G, Smith KJ, Merricks EP, Nichols TC, Ivanco D, Vehec D, Koerbel G, Althouse AD. Ragni MV, et al. Lancet Haematol. 2023 Aug;10(8):e612-e623. doi: 10.1016/S2352-3026(23)00119-9. Epub 2023 Jun 26. Lancet Haematol. 2023. PMID: 37385272 Free PMC article. Clinical Trial.
Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management in people with hemophilia A or B.
Pipe SW MD, Lissitchkov TJ, Georgiev P, Mangles S, Hegemann I, Trinchero A, Chowdary P, Forbes A, Feng L, Menapace LA, Kichou S, Andersson SR, Demissie M, Ragni MV. Pipe SW MD, et al. Among authors: ragni mv. Blood Adv. 2024 Dec 6:bloodadvances.2024013900. doi: 10.1182/bloodadvances.2024013900. Online ahead of print. Blood Adv. 2024. PMID: 39642315
Optimizing liver health before and after gene therapy for hemophilia A.
Ragni MV, Mead H, de Jong YP, Kaczmarek R, Leavitt AD, Long B, Nugent DJ, Sabatino DE, Fong S, von Drygalski A, Walsh CE, Luxon BA. Ragni MV, et al. Blood Adv. 2024 Oct 8;8(19):5203-5212. doi: 10.1182/bloodadvances.2024013059. Blood Adv. 2024. PMID: 38843379 Free PMC article. Review.
254 results